Research programme: VHH antibodies - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen
Alternative Names: Nanosized antibody programme - Scinai ImmunotherapeuticsLatest Information Update: 11 Sep 2023
At a glance
- Originator The Max Planck Society; University Medical Center Gottingen
- Developer Scinai Immunotherapeutics; The Max Planck Society; University Medical Center Gottingen
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Single-domain antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Asthma; Autoimmune disorders; Macular degeneration; Psoriasis; Psoriatic arthritis